Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: Spiolto

Study type

Observational

Funder types

Industry

Identifiers

NCT02850978

1237.34

Details and patient eligibility

About

Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting

Enrollment

1,335 patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with Long Acting Beta2 Agonist (LABA) or Long Acting Muscarinic Antagonist (LAMA).
Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time

Exclusion criteria

Patients who have been registered once in this study (i.e., re-entry of patients is not allowed).
Patients who are participating in a registry or clinical trial.
Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package insert for Tio+Olo FDC 5µg/5µg.